Locked nucleic acid as a novel class of therapeutic agents

Locked Nucleic Acid (LNA) is a nucleic acid analogue with unprecedented binding affinity and excellent specificity toward complementary RNA and DNA oligonucleotides. The remarkable properties of LNA have led to applications within various gene silencing strategies both in vitro and in vivo. In the present review, we highlight the uses of LNA for regulation of gene expression with emphasis on RNA targeting

Locked nucleic acid oligonucleotides towards clinical applications

Nucleic acid–based therapeutic technologies (Figure 9.1) have significantly advanced in the past two decades toward the treatment of many diseases. The first such drug to enter clinic was vitravene®, an antisense oligonucleotide for the treatment of cytomegalovirus retinitis [1]. Later, research on aptamers led to the marketing of macugen®, an inhibitor of vascular endothelial growth factor (VEGF) for the treatment of age related macular degeneration (AMD) [2]. Nucleic acid–based therapeutic approaches mainly include antisense [3,4], ribozymes [4], small interfering RNA (siRNA) [4–6], microRNA (miRNA) [7–10] targeting and aptamers [11–15]. Oligonucleotides composed of naturally occurring DNA or RNA nucleotides pose some limitations because of their poor RNA binding affinity, low degree of nuclease resistance, and low bioavilability. To overcome these limitations, chemically modified nucleic acids have been introduced, among which locked nucleic acid (LNA) [16–20] proved to be unique and is now used extensively for various applications in chemical biology [21–23]

In vitro incorporation of LNA nucleotides

An LNA modified nucleoside triphosphate 1 was synthesized in order to investigate its potential to act as substrate for DNA strand synthesis by polymerases. Primer extension assays for the incorporation experiments revealed that Phusion High Fidelity DNA polymerase is an efficient enzyme for incorporation of the LNA nucleotide and for extending strand to full length. It was also observed that pfu DNA polymerase could incorporate the LNA nucleotide but it failed to extend the strand to a full length product

Enzymatic synthesis of DNA strands containing α-L-LNA (α-L-configured locked nucleic acid) thymine nucleotides

We describe the first enzymatic incorporation of an α-L-LNA nucleotide into an oligonucleotide. It was found that the 5′-triphosphate of α-L-LNA is a substrate for the DNA polymerases KOD, 9°Nm, Phusion and HIV RT. Three dispersed α-L-LNA thymine nucleotides can be incorporated into DNA strands by all four polymerases, but they were unable to perform consecutive incorporations of α-L-LNA nucleotides. In addition it was found that primer extension can be achieved using templates containing one α-L-LNA nucleotide

Comments on photochromism of 3-(3-pyridyl)sydnone and 4-alkenylsydnones

The blue photochromism of sydnones 1, in particular 3-(3-pyridyl) sydnone 1a, has been ascribed to the formation of nitrosaminoketenes 2 as carriers of the blue color, allegedly supported by CNDO/S-CI and STO-3G calculations. New calculations at TD-B3LYP/6-31+G∗∗, RM06-2X/6-311+ +G(d,p), CAM-B3LYP/6-311++G(d,p), and CASPT2//CASSCF(6,6)/PVDZ levels demonstrate that the nitrosaminoketenes should be yellow and cannot possibly be blue. The sydnone photochromsm is not currently understood, and further experimental and computational investigation is required

Polymerase-directed synthesis of C5-ethynyl locked nucleic acids

Modified nucleic acids have considerable potential in nanobiotechnology for the development of nanomedicines and new materials. Locked nucleic acid (LNA) is one of the most prominent nucleic acid analogues reported so far and we herein for the first time report the enzymatic incorporation of LNA-U and C5-ethynyl LNA-U nucleotides into oligonucleotides. Phusion High Fidelity and KOD DNA polymerases efficiently incorporated LNA-U and C5-ethynyl LNA-U nucleotides into a DNA strand and T7 RNA polymerase successfully accepted the LNA-U nucleoside 5′-triphosphate as substrate for RNA transcripts

Rapid One-Step Selection Method for Generating Nucleic Acid Aptamers: Development of a DNA Aptamer against alpha-Bungarotoxin

Background: Nucleic acids based therapeutic approaches have gained significant interest in recent years towards the development of therapeutics against many diseases. Recently, research on aptamers led to the marketing of Macugen (R), an inhibitor of vascular endothelial growth factor (VEGF) for the treatment of age related macular degeneration (AMD). Aptamer technology may prove useful as a therapeutic alternative against an array of human maladies. Considering the increased interest in aptamer technology globally that rival antibody mediated therapeutic approaches, a simplified selection, possibly in one-step, technique is required for developing aptamers in limited time period

Development of transferrin receptor aptamers as drug delivery vehicles for the treatment of brain metastases

Affecting approximately up to 10-40% of all cancer patients, the prognosis for patients suffering from metastatic brain tumours is poor. Treatment of these metastatic tumours is greatly hindered by the presence of the blood brain barrier which restricts the overwhelming majority of small molecules from entering the brain. A novel approach to overcome this barrier is to target receptor mediated transport mechanisms present on the endothelial cell membranes, in particular the transferrin receptor. Given their specificity, safety profile and stability, nucleic acid-based therapeutics are ideal for this purpose. This review explores the development of bifunctional aptamers for the treatment of brain metastases

EpCAM immunotherapy versus specific targeted delivery of drugs

The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy

Enzymatic incorporations of LNA nucleotides into DNA strands

Unlocking uses of locked nucleic acids: LNA nucleoside 5′-triphosphates have been synthesized, and their ability to serve as substrates for polymerases have been investigated. Phusion high-fidelity DNA polymerase was found to be an efficient enzyme for incorporating LNA nucleoside 5′-triphosphates into DNA strands